Posterior Segment Toxicity after Gemcitabine and Docetaxel Chemotherapy
نویسندگان
چکیده
منابع مشابه
Refractive Error and Anterior Segment Parametric Changes in Patients with Posterior Capsular Opacification after Nd: YAG Laser Posterior Capsulotomy
Background and Objective: Cataract is one of the most common causes of blindness in the world, and posterior capsular opacification (PCO) is the most common complication after cataract surgery. Nd: YAG laser posterior capsulotomy is a standard method for the treatment of PCO. The aim of this study was to investigate the effects of Yas laser capsulotomy on anterior segment parameters and lenticu...
متن کاملGemcitabine and docetaxel in metastatic breast cancer.
Use of the gemcitabine (Gemzar) plus docetaxel (Taxotere) combination in metastatic breast cancer is motivated by the different mechanisms of action of the drugs, partially nonoverlapping toxicity profiles, and good single-agent activities of both drugs in treatment-naive and anthracycline-pretreated patients. In phase II trials, combinations of gemcitabine at 900 or 1,000 mg/m2 on days 1 and 8...
متن کاملA phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.
BACKGROUND A phase I/II study of docetaxel (DOC) and gemcitabine (GEM) combination for treatment-resistant ovarian cancer (OC) was conducted. MATERIALS AND METHODS Eligible patients exhibited recurrent OC within 12 months after initial treatment, or after more than 2 chemotherapy regimens. Planned dose levels (DL) were as follows: DOC 70 mg/m(2), GEM 800 mg/m(2) (DL1); DOC 70 mg/m(2), GEM 100...
متن کاملTriplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. Tw...
متن کاملGemcitabine-induced pulmonary toxicity.
BACKGROUND Gemcitabine is the only approved cytotoxic agent for the treatment of pancreatic cancer by the Food and Drug Administration. In addition, gemcitabine is also commonly used for the management of breast, ovarian, and non-small cell lung cancer. Myelosuppression is the most common toxicity of gemcitabine therapy. Pulmonary toxicities due to gemcitabine have, however, been reported. Dysp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Optometry and Vision Science
سال: 2015
ISSN: 1040-5488
DOI: 10.1097/opx.0000000000000571